Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | DUT | P33316 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13626717 | 1.00 | RNASE1 (0.53) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13626065 | 1.00 | RNASE1 (0.53) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL4339980 | 1.00 | RNASE1 (0.53) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL19813627 | 0.91 | RNASE1 (0.53) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13626718 | 0.90 | DUT (0.46) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13637227 | 0.90 | DUT (0.46) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL19813629 | 0.90 | RNASE1 (0.54) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL19813632 | 0.90 | RNASE1 (0.54) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL12930558 | 0.89 | DUT (0.47) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13901234 | 0.89 | RNASE1 (0.52) | RNASE1SLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250283094-A1 | Modified Nucleosides | SOMALOGIC OPERATING CO., INC. (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4323374-A1 | MODIFIED NUCLEOSIDES | SomaLogic Operating Co., Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221241-A1 | MODIFIED NUCLEOSIDES | SOMALOGIC OPERATING CO., INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| EP-2123759-A2 | Stabilized RNAS as transfection controls and silencing reagents | Dharmacon, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090280567-A1 | STABILIZED SIRNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS | DHARMACON, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| EP-1718747-B1 | STABILIZED RNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS | DHARMACON INC (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20070269889-A1 | Stabilized siRNAs as transfection controls and silencing reagents | DHARMACON, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| EP-1718747-A2 | STABILIZED RNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS | Dharmacon, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005078094-A2 | STABILIZED RNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS | DHARMACON, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280567-A1 | STABILIZED SIRNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS | PHAX, NSUN2, UPF1 | RNASE1 220/4885SLC28A1 276/4885SLC28A2 271/4885 |
| US-20250283094-A1 | Modified Nucleosides | NT5C3B, PNP, TYMP | RNASE1 174/4885SLC28A1 72/4885SLC28A2 76/4885 |
| US-20070269889-A1 | Stabilized siRNAs as transfection controls and silencing reagents | PHAX, NSUN2, UPF1 | RNASE1 220/4885SLC28A1 276/4885SLC28A2 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.